Regina Renee Nicholes, | |
115 W Oak St, Amite, LA 70422-2715 | |
(985) 474-2114 | |
Not Available |
Full Name | Regina Renee Nicholes |
---|---|
Gender | Female |
Speciality | Technician - Personal Care Attendant |
Location | 115 W Oak St, Amite, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1396201794 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | 20100159 (Louisiana) | Secondary |
3747P1801X | Technician - Personal Care Attendant | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Regina Renee Nicholes, 178 Baker Rd, Independence, LA 70443-4742 Ph: (985) 474-2114 | Regina Renee Nicholes, 115 W Oak St, Amite, LA 70422-2715 Ph: (985) 474-2114 |
News Archive
Amgen and Wyeth Pharmaceuticals, a division of Wyeth have announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group.
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.
Fears of a link between testosterone replacement therapy and cardiovascular risk are misplaced, according to a review published in this month's Mayo Clinic Proceedings. The therapy has come under widespread scrutiny in recent months, including by a federal Food and Drug Administration panel convened last fall.
Researchers at the Technion-Israel Institute of Technology have made a breakthrough that could lead to radical changes in the design and effectiveness of inhalation masks for infants.
Starting medication for multiple sclerosis (MS) in people who show the beginning signs of the disease is associated with prolonging the time before the disease is definitively diagnosed, according to a long-term study published in the August 10, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.
› Verified 2 days ago